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A B S T R A C T
We investigated if the use of two tumor markers, galectin-3 and CD44v6, could improve diagnostic accuracy of thy-
roid fine needle aspiration biopsy (FNAB) in cytologically indeterminate lesions (CIL). 351 patients with CIL [cellular
follicular lesion/suspicious follicular neoplasm/suspicious Hürthle cell neoplasm (CFL/sFN/sHCN), Hürthle cell neo-
plasm (HCN), and follicular neoplasm (FN)] and surgical follow-up were investigated. 251 patients had FNAB diagno-
ses made without help of tumor markers and the rest of 100 patients had FNAB diagnoses made with a known expres-
sion of tumor markers determined by the reverse transcription (RT)-PCR. Risk of malignancy in all 351 patients with
CIL was 6.8%. In the group with FNAB made without RT-PCR, there were 140 CFL/sFN/sHCN with the risk of malig-
nancy of 4.2%, 92 FN with the risk of malignancy of 13.0%, and 19 HCN with the risk of malignancy of 5.2%. In the
group with FNAB made with RT-PCR, there were 49 CFL/sFN/sHCN with the risk of malignancy of 2.0%, 40 FN with
the risk of malignancy of 7.5%, and 11 HCN with the risk of malignancy of 9.0%. In the group with at least one positive
tumor marker (N=69), the risk of malignancy was 3.1% for CFL/sFN/sHCN, 11.1% for FN, and 10.0% for HCN. In the
group with negative tumor markers (N=31) there were no malignancies. The use of tumor markers, galectin-3 and
CD44v6, determined by RT-PCR improves only sensitivity of thyroid FNAB in CIL. In most patients with CIL, and nega-
tive both tumor markers, conservative approach is advisable.
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Introduction
Fine-needle aspiration biopsy (FNAB) of the thyroid
is a rapid, minimally invasive, accurate, and inexpensive
procedure for evaluation of thyroid nodules1. The main
goal of thyroid FNAB is to distinguish nodules that re-
quire surgery from those that do not, thereby decreasing
the number of diagnostic surgical procedures2–6. How-
ever, FNAB of the thyroid is indeterminate for neoplasia
in 5–29% of patients7–9. Surgical excision, with its atten-
dant high cost and potential morbidity, usually is re-
quired to fully evaluate these lesions.
The most controversial decision is managing patients
with cytologically indeterminate thyroid lesions. The di-
agnosis of follicular thyroid carcinomas is made only by
identifying histopathologic infiltration into blood vessels
or capsule, or by detection of distant metastasis. Cyto-
logic diagnosis has its limitations because of the similar
cytologic findings in aspirates from adenomatoid nod-
ules, follicular adenomas, well-differentiated follicular
carcinomas and papillary carcinomas of the follicular
variant or with a prominent follicular component4,10–14.
Reverse-transcription polymerase chain reaction (RT-
-PCR) has been used to search for the expression of po-
tential thyroid carcinoma associated molecular markers
within the cells obtained from FNAB of the thyroid15,16.
Among them the most promising were two lectin-related
molecules: the beta-galactoside-binding protein galectin-
-3 and CD44v6, an isoform of CD44, the cell-surface re-
ceptor for hyaluronic acid17–21.
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We investigated whether the use of two tumor mark-
ers, galectin-3 and CD44v6 determinated by RT-PCR,
could improve diagnostic accuracy of FNAB in cytologi-
cally indeterminate thyroid lesions.
Patients and Methods
We undertook a retrospective search of all patients
who underwent a thyroid surgical procedure at University
Hospital »Sestre milosrdnice«, Zagreb between March
1995 and April 2008 and had a preoperative FNAB diag-
nosis of cytologically indeterminate thyroid lesion. FNAB
diagnoses included cellular follicular lesion/suspicious
follicular neoplasm/suspicious Hürthle cell neoplasm
(CFL/sFN/sHCN), Hürthle cell neoplasm (HCN), and
follicular neoplasm (FN).
351 patients with cytologically indeterminate lesions
and surgical follow up were found. 251 patients had
FNAB diagnoses made without help of tumor markers
and the rest of 100 patients had FNAB diagnoses made
with a known expression of tumor markers, galectin-3
and CD44v6, determined by the RT-PCR.
We investigated the risk of malignancy in both
groups of patients (separately by the type of FNAB diag-
nosis), and then compare the risk of malignancy in pa-
tients with negative tumor markers, patients with at
least one positive tumor marker and patients without
RT-PCR results.
Aspirates were obtained by ultrasound guided FNAB
and smeared for conventional cytology (MGG staining).
One to three punctures per nodule were performed de-
pending on the size of the nodule. In patients with
RT-PCR analysis, the leftover material in the needle was
used for RT-PCR analysis. RT-PCR analysis was per-
formed as described by Samija et al.22. The value of
marker analysis was considered positive if at least one
marker, galectin-3 or CD44v6, was positive.
Statistical analysis was performed using Fisher’s exact
test. A p value less than 0.05 were considered significant.
Definition of the diagnostic categories for
indeterminate thyroid lesions
CFL is best described as »probably neoplastic«. FNAB
shows relatively abundant, slightly atypical, follicular
cells and scant colloid.
FN is best described as »probably malignant«. It in-
cludes follicular adenoma and follicular carcinoma. It’s
characterized by irregular microfollicles with nuclear
overlap and central, dense colloid, in association with cy-
tologic nuclear atypia.
HCN includes Hürthle cell adenoma and Hürthle cell
carcinoma. It’s characterized by a single cell population
of Hürthle cell in a background of minimal or absent
colloid.
FNA reports of »sFN/sHCN« include cytomorphologic
features of CFL and FN/HCN as well.
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TABLE 1
CYTOLOGIC DIAGNOSIS VERSUS PATHOHISTOLOGICAL DIAGNOSES IN PATIENTS WITH FNAB DIAGNOSIS MADE WITHOUT RT-PCR
Cytologic
diagnosis
PHD
Total
Risk of
malignancyNG HT FA HCA PC FC HCC MC
CFL/FN?/HCN? 54 2 64 14 4 1 1 0 140 4.2%
FN 20 0 57 3 4 5 2 1 92 13.0%
HCN 7 0 3 8 1 0 0 0 19 5.2%
Total 81 2 124 25 9 6 3 1 251 7.6%
PHD – pathohistological diagnosis, NG – nodular goiter, HT – Hashimoto thyroiditis, FA – follicular adenoma, HCA – Hürthle cell
adenoma, PC – papillary carcinoma, FC – follicular carcinoma, HCC – Hürthle cell carcinoma, MC – medullary carcinoma, CFL – cellu-
lar follicular lesion, FN – follicular neoplasm, HCN – Hürthle cell neoplasm
TABLE 2
CYTOLOGIC DIAGNOSIS VERSUS PATHOHISTOLOGICAL DIAGNOSES IN PATIENTS WITH FNAB DIAGNOSIS MADE WITH RT-PCR
Cytologic
diagnosis
PHD
Total
Risk of
malignancyNG HT FA HCA PC FC HCC MC
CFL/FN?/HCN? 21 1 23 3 1 0 0 0 49 2.0%
FN 14 0 20 3 1 1 0 1 40 7.5%
HCN 2 1 1 6 0 0 1 0 11 9.0%
Total 37 2 44 12 2 1 1 1 100 5.0%
PHD – pathohistological diagnosis, NG – nodular goiter, HT – Hashimoto thyroiditis, FA – follicular adenoma, HCA – Hürthle cell
adenoma, PC – papillary carcinoma, FC – follicular carcinoma, HCC – Hürthle cell carcinoma, MC – medullary carcinoma, CFL – cellu-
lar follicular lesion, FN – follicular neoplasm, HCN – Hürthle cell neoplasm
Results
Overall risk of malignancy in all 351 patients with cy-
tologically indeterminate lesions was 6.8%. In the group
of patients with FNAC diagnosis made without RT-PCR,
there were 140 diagnoses of CFL/sFN/sHCN with the
risk of malignancy of 4.2%, 92 diagnoses of FN with the
risk of malignancy of 13.0%, and 19 diagnoses of HCN
with the risk of malignancy of 5.2% (Table 1). In the
group of patients with FNAC diagnosis made with RT-
-PCR, there were 49 diagnoses of CFL/sFN/sHCN with
the risk of malignancy of 2.0%, 40 diagnoses of FN with
the risk of malignancy of 7.5%, and 11 diagnoses of HCN
with the risk of malignancy of 9.0% (Table 2). The risks
of malignancy in these two groups didn’t differ signifi-
cantly (p>0.05). In the group of patients with at least
one positive tumor marker (N=69), the risk of malig-
nancy was 3.1% for diagnoses of CFL/sFN/sHCN, 11.1%
for diagnoses of FN, and 10.0% for diagnoses of HCN (Ta-
ble 3). The risk of malignancy in this group of patients
(7.2%) didn’t differ significantly (p>0.05) from the risk
of malignancy in the previous two groups of patients (7.6
and 5.0, respectively). In the group of patients with nega-
tive both tumor markers (N=31) there were no malig-
nancies (Table 4). Although there was a strong tendency
(p=0.1241), we found no statistically significant (p>
0.05) difference between the group of patients with nega-
tive both tumor markers and the group of patients with
at least one positive tumor marker, according to the risk
of malignancy.
Sensitivity and specificity of investigated tumors
markers, galectin-3 and CD44v6, when the RT-PCR was
considered positive for malignancy if at least one tumor
marker is positive, was 100% and 60%, respectively.
Discussion and Conclusion
The ultimate goal in the preoperative evaluation of
thyroid nodules is to accurately designate lesions as be-
nign or malignant, and thereby allow malignant lesions
to be surgically excised. Clinical features can help to pre-
dict an increase or decrease in the likelihood of cancer in
a nodule, but these parameters have limited utility23,24.
Standard cytological evaluation of thyroid nodules, even
under the guidance of a highly trained cytopathologist,
cannot definitively distinguish benign from malignant
thyroid lesions in all cases. Thyroid cancer markers, such
as CD44v6 and galectin-3 used in this study, are there-
fore in a focus of interest as potential tools to enhance
the preoperative evaluation of thyroid nodules.
In our study, overall risk of malignancy in 351 pa-
tients with cytologically indeterminate lesions was 6.8%.
In other publications, the possibility of malignancy in
this cytologic category ranged from 0 to 43%, with a me-
dian of 3% and a mean of 12%9.
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TABLE 3
CYTOLOGIC DIAGNOSIS VERSUS PATHOHISTOLOGICAL DIAGNOSES IN PATIENTS WITH FNAB DIAGNOSIS AND EITHER GALECTIN-3
OR CD44V6 POSITIVE BY RT-PCR
Cytologic
diagnosis
PHD
Total
Risk of
malignancyNG HT FA HCA PC FC HCC MC
CFL/FN?/HCN? 13 1 15 2 1 0 0 0 32 3.1%
FN 9 0 14 1 1 1 0 1 27 11.1%
HCN 1 1 1 6 0 0 1 0 10 10.0%
Total 23 2 30 9 2 1 1 1 69 7.2%
PHD – pathohistological diagnosis, NG – nodular goiter, HT – Hashimoto thyroiditis, FA – follicular adenoma, HCA – Hürthle cell
adenoma, PC – papillary carcinoma, FC – follicular carcinoma, HCC – Hürthle cell carcinoma, MC – medullary carcinoma, CFL – cellu-
lar follicular lesion, FN – follicular neoplasm, HCN – Hürthle cell neoplasm
TABLE 4
CYTOLOGIC DIAGNOSIS VERSUS PATHOHISTOLOGICAL DIAGNOSES IN PATIENTS WITH FNAB DIAGNOSIS AND BOTH GALECTIN-3
AND CD44V6 NEGATIVE BY RT-PCR
Cytologic
diagnosis
PHD
Total
Risk of
malignancyNG HT FA HCA PC FC HCC MC
CFL/FN?/HCN? 8 0 8 1 0 0 0 0 17 0 %
FN 5 0 6 2 0 0 0 0 13 0 %
HCN 1 0 0 0 0 0 0 0 1 0 %
Total 14 0 14 3 0 0 0 0 31 0 %
PHD – pathohistological diagnosis, NG – nodular goiter, HT – Hashimoto thyroiditis, FA – follicular adenoma, HCA – Hürthle cell
adenoma, PC – papillary carcinoma, FC – follicular carcinoma, HCC – Hürthle cell carcinoma, MC – medullary carcinoma, CFL – cellu-
lar follicular lesion, FN – follicular neoplasm, HCN – Hürthle cell neoplasm
In our study, sensitivity and specificity of galectin-3
and CD44v6 analyzed by RT-PCR for distinguishing be-
nign from malignant lesions among cytologically indeter-
minate thyroid lesions was 100% and 60%, respectively.
It is similar to the results of Maruta et al.25 using the
immunostaining method, who found sensitivity and spe-
cificity of either galectin-3 or CD44v6 of 97% and 52%,
respectively, for distinguishing follicular carcinoma
among FNAB diagnoses of follicular tumors. The lower
specificity could be explained by the presence of macro-
phages and Hürthle cells in some samples. It has been
shown that macrophages and Hürthle cells could be re-
sponsible for positive results of galectin-3 and CD44v6 in
benign thyroid lesions26.
The risk of malignancy in the group of patients with
FNAB diagnosis made without RT-PCR (7.6%) and the
risk of malignancy in the group of patients with FNAC
diagnosis made with RT-PCR (5.0%) didn’t differ signifi-
cantly, presumably because patients were referred to sur-
gical removal according solely to FNAB diagnosis.
Patients with at least one positive tumor marker and
FNAB diagnoses of CFL/sFN/sHCN had the low risk of
malignancy (3.1%) and could be monitored by close fol-
low-up. The risk of malignancy (11.1%) for patients with
at least one positive tumor marker and FNAB diagnoses
of FN and the risk of malignancy (10.0%) for FNAB diag-
noses of HCN were significantly higher and require sur-
gical treatment.
In the group of patients with cytologically indetermi-
nate lesions and both tumor markers negative, there
were no malignancies and these patients could be moni-
tored in follow-up evaluations.
In conclusion, results of this study demonstrate that
RT-PCR improve diagnostic accuracy of FNAB avoiding
unnecessary surgeries for many patients with cytologi-
cally indeterminate lesions.
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POUZDANOST CITOLO[KE PUNKCIJE SA I BEZ UPOTREBE TUMORSKIH BILJEGA
KOD CITOLO[KI NEODRE\ENIH PROMJENA [TITNJA^E
S A @ E T A K
Istra`ivali smo da li upotreba dvaju tumorskih biljega, galektina-3 i CD44v6, mo`e pobolj{ati pouzdanost citolo{ke
dijagnoze (CD) {titnja~e kod citolo{ki neodre|enih nalaza (CNN) u pogledu malignosti. Analiziran je 351 pacijent s
CNN [celularna folikularna promjena/suspektan folikularni tumor/suspektan Hürthleov tumor (CFP, sFT, sHT),
Hürthleov tumor (HT) i folikularni tumor (FT)] kojemu je promjena kirur{ki odstranjena. Kod 251 pacijenta CD je
postavljena bez upotrebe tumorskih biljega dok je kod ostalih 100 pacijenata dijagnoza postavljena uz poznatu vrijed-
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nost tumorskih biljega odre|enih uz pomo} RT-PCR. Rizik malignosti kod svih pacijenata s CNN bio je 6,8%. U skupini
s CD postavljenom bez RT-PCR, bilo je 140 CFP/sFT/sHT uz rizik malignosti od 4,2%, 92 FT uz rizik malignosti od
13,0%, te 19 HT uz rizik malignosti od 5,2%. U skupini s CD postavljenom sa RT-PCR, bilo je 49 CFP/sFT/sHT uz rizik
malignosti od 2,0%, 40 FT uz rizik malignosti od 7,5%, te 11 HT uz rizik malignosti od 9,0%. U skupini sa barem jednim
pozitivnim biljegom (N=69), rizik malignosti bio je 3,1% za CFP/sFT/sHT, 11,1% za FT, te 10,0% za HT. U skupini sa
negativna oba tumorska biljega (N=31) nije bilo malignih tumora. Mo`e se zaklju~iti da upotreba tumorskih biljega,
galektina-3 i CD44v6, pobolj{ava samo senzitivnost CD {titnja~e kod CNN. Kod ve}ine pacijenata sa CNN i negativna
oba tumorska biljega mo`e se preporu~iti konzervativni pristup.
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